Featured Research

from universities, journals, and other organizations

Most Smokers Continue To Smoke After Heart Procedures

Date:
March 11, 1998
Source:
Mayo Clinic
Summary:
The people who need to stop smoking the most are the least likely to stop says a new Mayo Clinic study of heart patients. The study appears in the March issue of Mayo Clinic Proceedings.

ROCHESTER, MINN. -- The people who need to stop smoking the most are the least likely to stop says a new Mayo Clinic study of heart patients. The study appears in the March issue of Mayo Clinic Proceedings.

Mayo researchers looked at the smoking patterns of more than 5,400 patients who had angioplasties (heart vessel clearing procedures) at Mayo Clinic over a 16-year period. They found that 21 percent of these patients were smokers at the time of the procedure. Of this group:

* 63 percent continued to smoke after their procedure

* 51 percent continued to smoke even after a prior heart attack

* Less than 10 percent sought help from the Mayo Nicotine Dependence Center

They found that the patients most likely to continue smoking were those who would benefit most from smoking cessation -- patients who were younger, smoked the most and had more risk factors for development of coronary artery disease (diabetes, hypertension, high cholesterol and family history of heart disease).

"The study provides some good baseline information on the kind of problem we're up against," says Dr. Gerald Gau, a cardiologist and one of the study authors. "Even with these life-threatening kind of events, people continue to smoke. Nicotine is a very addictive drug."

The researchers say that angioplasties should be considered a "window of opportunity" to refer patients to smoking cessation programs. "The study clearly shows that if we don't take aggressive action at these times when we've got their attention, most smokers are going to keep right on smoking," says Dr. Gau.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Most Smokers Continue To Smoke After Heart Procedures." ScienceDaily. ScienceDaily, 11 March 1998. <www.sciencedaily.com/releases/1998/03/980311072724.htm>.
Mayo Clinic. (1998, March 11). Most Smokers Continue To Smoke After Heart Procedures. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1998/03/980311072724.htm
Mayo Clinic. "Most Smokers Continue To Smoke After Heart Procedures." ScienceDaily. www.sciencedaily.com/releases/1998/03/980311072724.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins